Paloma Partners’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-16,844
| Closed | -$1.18M | – | 2048 |
|
|
2020
Q2 | $1.18M | Buy |
+16,844
| New | +$1.18M | 0.02% | 755 |
|
|
2020
Q1 | – | Sell |
-9,118
| Closed | -$593K | – | 1478 |
|
|
2019
Q4 | $593K | Sell |
9,118
-849
| -9% | -$55.2K | 0.01% | 1038 |
|
|
2019
Q3 | $619K | Sell |
9,967
-22,543
| -69% | -$1.4M | 0.01% | 771 |
|
|
2019
Q2 | $2.32M | Buy |
+32,510
| New | +$2.32M | 0.04% | 292 |
|
|
2018
Q4 | – | Sell |
-3,280
| Closed | -$562K | – | 1224 |
|
|
2018
Q3 | $562K | Buy |
+3,280
| New | +$562K | 0.01% | 719 |
|
|
2017
Q4 | – | Sell |
-3,527
| Closed | -$300K | – | 1465 |
|
|
2017
Q3 | $300K | Buy |
+3,527
| New | +$300K | ﹤0.01% | 1217 |
|
|
2017
Q1 | – | Sell |
-4,660
| Closed | -$295K | – | 1584 |
|
|
2016
Q4 | $295K | Buy |
+4,660
| New | +$295K | ﹤0.01% | 1255 |
|
|
2016
Q2 | – | Sell |
-3,073
| Closed | -$206K | – | 1797 |
|
|
2016
Q1 | $206K | Sell |
3,073
-614
| -17% | -$41.2K | ﹤0.01% | 1294 |
|
|
2015
Q4 | $249K | Buy |
+3,687
| New | +$249K | 0.01% | 1108 |
|
|
2015
Q1 | – | Sell |
-16,609
| Closed | -$551K | – | 1194 |
|
|
2014
Q4 | $551K | Buy |
+16,609
| New | +$551K | 0.02% | 545 |
|
|
2014
Q2 | – | Sell |
-56,105
| Closed | -$2.35M | – | 1085 |
|
|
2014
Q1 | $2.35M | Sell |
56,105
-28,854
| -34% | -$1.21M | 0.15% | 113 |
|
|
2013
Q4 | $2.79M | Buy |
84,959
+36,067
| +74% | +$1.18M | 0.14% | 148 |
|
|
2013
Q3 | $1.32M | Buy |
48,892
+8,817
| +22% | +$238K | 0.05% | 277 |
|
|
2013
Q2 | $936K | Buy |
+40,075
| New | +$936K | 0.05% | 258 |
|